Compare JBI & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | AGMB |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 586.7M | 576.2M |
| IPO Year | 2021 | 2024 |
| Metric | JBI | AGMB |
|---|---|---|
| Price | $4.67 | $7.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.42 | ★ $37.67 |
| AVG Volume (30 Days) | ★ 1.8M | 101.1K |
| Earning Date | 11-10-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.26 | N/A |
| Revenue Next Year | $2.23 | N/A |
| P/E Ratio | $62.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.01 | $6.52 |
| 52 Week High | $7.48 | $17.82 |
| Indicator | JBI | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 54.47 | 43.83 |
| Support Level | $4.13 | N/A |
| Resistance Level | $5.60 | $9.55 |
| Average True Range (ATR) | 0.20 | 0.82 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 55.81 | 52.01 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. It provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.